Glenmark Launches Adapalene Gel Pump Packs; Shares Rise 0.33%

Mumbai, October 6: Glenmark Pharmaceuticals Limited said its US-based subsidiary Glenmark Therapeutics Inc. has launched Adapalene Gel USP, 0.1% in new pump packs in the US over-the-counter (OTC) market.

According to the company’s exchange disclosure, Glenmark’s Adapalene Gel USP, 0.1% contains the same active ingredient as Differin Gel, 0.1%. The new packaging is intended to provide consumers with a more convenient way to dispense the topical product.

The launch expands Glenmark’s presence in the US dermatology and consumer healthcare market, where the company has been building its portfolio of affordable treatment options.

Stock Market Snapshot

The Glenmark share price stood at ₹2,302.50 as of 9:54:46 AM IST on October 6, 2026, according to the market data.

The stock was up ₹7.50, or 0.33%, at the time. Shares recovered from lower levels during the morning and moved back above ₹2,300.

The Glenmark share price movement came as the company announced the US launch of the new Adapalene Gel pump packs.

Adapalene Gel Targets US OTC Dermatology Market

Glenmark said the Differin Gel 0.1% OTC market recorded annual sales of approximately $45.8 million for the 52-week period ended September 5, 2026, according to Nielsen syndicated data.

The company’s Adapalene Gel USP, 0.1% is being introduced in 15-gram and 45-gram pump packs. The product is marketed only for the indications listed in Glenmark’s approved drug facts label.

The company said the new format gives consumers an alternative dispensing option while adding to its US dermatology portfolio.

Glenmark Expands US Consumer Health Portfolio

Marc Kikuchi, President and Business Head, North America, said the pump-pack launch is intended to make the product easier to dispense while supporting the company’s broader US dermatology business.

Glenmark Pharmaceuticals is a research-led pharmaceutical company with operations across branded, innovative, generics and consumer health products. Its portfolio covers areas including respiratory, dermatology, oncology and women’s health.

The company operates manufacturing facilities across several countries and has a presence in more than 80 countries, according to its corporate profile.

Conclusion

Glenmark’s launch of Adapalene Gel USP, 0.1% in new pump packs gives the company another offering in the US OTC dermatology market, where the comparable Differin Gel 0.1% category recorded about $45.8 million in annual sales for the latest 52-week period. The Glenmark share price was up 0.33% at ₹2,302.50 as of 9:54:46 AM IST on October 6, 2026.

Source:

• https://www.nseindia.com/get-quote/equity/GLENMARK/Glenmark-Pharmaceuticals-Limited
• https://nsearchives.nseindia.com/corporate/GLENMARK_06102026083500_SEIntimation_06102026.pdf